Alpine Immune Sciences initiated with an Outperform at Raymond James. Raymond James analyst Reni Benjamin initiated Alpine Immune Sciences (ALPN) with an Outperform and $13 price target. Benjamin said the company has a unique platform technology utilizing directed evolution to generate multi-functional single compounds. The analyst believes the platform is on the verge of a significant validation inflection point given a “slew” of preclinical results demonstrating activity in both autoimmune disease adn oncology, combined with early stage partnership with Kite, a Gilead (GILD) company.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.